Abstract
Objective To analyze quantitatively and comparatively the deaths by COVID-19 of the four largest municipalities in the North of Rio de Janeiro and Baixada Litorânea of Rio de Janeiro, within the national context.
Methods We used data from the Civil Registry and demographic information to elaborate a general picture of the pandemic up to the 31st epidemiological week in several aspects: evolution, scope, age, sex, race and impact on other causes of death.
Results We characterized the evolution of the pandemic. We found an exponential dependence on the mortality rate by age and a higher lethality in the male population. We determined that COVID-19 represents an important fraction of the causes of death in 2020, being associated with a significant excess of deaths in relation to 2019 and also with the change in mortality patterns due to other causes.
Conclusion Mortality is an effective and powerful indicator for understanding the infection and its pandemic, and it must be taken into account during the construction of public policies to deal with it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is part of the research project entitled "Coping with COVID-19 in the North Fluminense Region and Baixada Litoranea: Actions, perspectives and impacts", approved by the Research Ethics Committee of the Federal University of Rio de Janeiro / Campus UFRJ-Macae Professor Aloisio Teixeira, under CAAE: 32186520.7.0000.5699.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are publicly available.
